ReviewMolecular pharmacology2008
Protein-protein interactions and dopamine D2 receptor signaling: a calcium connection.
Review in Molecular pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 15 citations in OpenAlex.
- Associative memory neurons are recruited in PFC-centered circuits to encode schizophrenia-like behavior by dopaminergic receptor-II.Molecular psychiatry · 2026Article
- Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop.The Journal of biological chemistry · 2016Article
- Modulatory Effects of Dopamine D2 Receptors on Spreading Depression in Rat Somatosensory Neocortex.Basic and clinical neuroscience · 2014Article
- Levels of S100B are raised in female patients with schizophrenia.BMC psychiatry · 2013Article
- Novel migrating mouse neural crest cell assay system utilizing P0-Cre/EGFP fluorescent time-lapse imaging.BMC developmental biology · 2011Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The third cytoplasmic loop is a crucial site of physical contact between some G protein-coupled receptors (GPCRs) and their respective G proteins. However, interactions not only occur among these proteins but also involve a number of additional protein binding partners. Modulation of these protein-protein interactions may represent an important new avenue of pharmacotherapy through which signaling of GPCRs can be modulated. In the current issue of Molecular Pharmacology, Liu et al. (p. 371) report that dopamine D(2) receptors interact with the Ca(2+) binding protein S100B. Using the third intracellular loop of the dopamine D(2) receptor as bait in a bacterial two-hybrid system, S100B was determined to be a potential binding partner. They used pull-down assays both in vitro and in vivo to confirm the interaction and define its specificity. Neither the D(3) nor the D(4) receptor expresses the motif conferring the interaction, and peptides based on the third intracellular loop of the D(3) receptor did not pull down S100B. Some groups might stop there, but Liu and colleagues moved on to demonstrate colocalization of the D(2) receptor and S100B by immunostaining. Functional assays were then used to show that coexpression of S100B with the D(2) receptor increases the ability of D(2) receptors to activate ERK and to inhibit adenylyl cyclase. These data suggest that S100B coexpression may serve as an important mediator of D(2) receptor signaling efficacy in the brain. These interactions contribute to cellular, regional, and developmental differences in D(2) receptor activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.